Medincell S.A.

WHO'M
ai
Digital Profiler. Einfach den AI-Button klicken
CUSIP
F6104D107
SEDOL
N/A
CIK
N/A
www.medincell.com
LEI:
©
FIGI: BBG00M0C8GJ0
MEDCL
Medincell S.A.
GICS: - · Sektor: - · Sub-Sektor: -
NAME
Medincell S.A.
ISIN
FR0004065605
TICKER
MEDCL
MIC
XPAR
REUTERS
MEDCL.PA
BLOOMBERG
MEDCL FP
BUILD THEMEFOLIO IDEEN TEILEN DISKUTIEREN
HEBEL INVESTIEREN
GIF DE 728x90
Financial Intelligence
360° iHub Crowd ATH Tracker Index Tracker ETF TF Spicy X-Billboard
FÜR INVESTOREN
FÜR TRADER
Börsenhandel Warrants
Der X-News Explorer ist die ultimative Informationsquelle für börsenaffine Anleger, die sich schnell und komfortabel einen Überblick über die aktuelle Nachrichtenlage eines börsennotierten Unternehmens verschaffen möchten. Ihnen stehen hier verschiedene Newswire-Services zur Verfügung. Wird ein News-Alert angezeigt, liegen Unternehmensnachrichten vor, die Sie möglicherweise interessieren könnten. Dieser Service wird Ihnen von BusinessWire bereitgestellt.
Mo., 04.11.2024       Medincell
FR0004065605

Medincell (Paris:MEDCL): ACCESS HERE THE COMPLETE PRESS RELEASE TEV-‘749 / mdc-TJK - Investigational Olanzapine Long-Acting Injectable Teva presented positive data from the initial period of the Phase 3 SOLARIS trial evaluating Olanzapine LAI in adult patients diagnosed with schizophrenia. Findings demonstrate significant improvement in soci...
weiterlesen
Medincell
Research & Analysen Termsheet Terminal
Permalink
Mo., 23.09.2024       Medincell
FR0004065605

New data presented by Teva at ECNP 2024* demonstrate switching to UZEDY at four weeks after the last dose of once-monthly Perseris® (RBP-7000) provided the most comparable pharmacokinetic (PK) profile based on relevant simulations, with comparable doses identified. Perseris manufacturer announced in July 2024 the discontinuation of its commercial...
weiterlesen
Medincell
Research & Analysen Termsheet Terminal
Permalink
Mo., 23.09.2024       Medincell
FR0004065605

Teva presented at ECNP 2024* new positive efficacy, safety, and tolerability results for Phase 3 SOLARIS trial evaluating Olanzapine LAI (TV-‘749 / mdc-TJK) in adult patients diagnosed with schizophrenia. Richard Malamut, Chief Medical Officer of Medincell, said: “In addition to publishing the positive efficacy results for the primary and seconda...
weiterlesen
Medincell
Research & Analysen Termsheet Terminal
Permalink
Do., 05.09.2024       Medincell
FR0004065605

Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), announced during the 22nd Annual Global Healthcare Conference held yesterday that c.99% of the targeted injections for submission have been performed as of today (replay available here). Teva also confirmed that the full submission safety results a...
weiterlesen
Medincell
Research & Analysen Termsheet Terminal
Permalink
Di., 03.09.2024       Medincell
FR0004065605

Collaboration with AbbVie Initiation of preclinical and supportive CMC* work to advance LAI candidate into clinical development Collaboration with Teva UZEDY® (risperidone LAI) Reaffirming revenue guidance for 2024 by Teva: c.$80 million Exploring an additional indication for the treatment of Bipolar I Disorder in adults Olanza...
weiterlesen
Medincell
Research & Analysen Termsheet Terminal
Permalink
We are different
OPEN FINANCIAL
DATA & KNOWLEDGE HUB
We make the difference
Informationen zu Product Placements